IM Cannabis Corp is a leading vertically integrated cannabis company that specializes in the cultivation, production, and distribution of medical and recreational cannabis products. Based in Canada and with operations extending into international markets, the company focuses on providing high-quality cannabis to consumers while adhering to regulatory standards. IM Cannabis prioritizes innovation and sustainability in its cultivation practices and offers a diverse range of products, including dried flower, oils, and infused edibles, all aimed at enhancing the wellness and lifestyle of its customers. Through strategic partnerships and an expanding global footprint, the company aims to become a key player in the evolving cannabis industry. Read More
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
International medical cannabis company IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) announced on Thursday its financial results for the third quarter ended Sept. 30, 2024. The company reported revenue from Germany grew 66% year-over-year, reaching CA$5.8 million ($4.1 million). "While the 66% growth we delivered in Germany, to reach $5.8M this quarter is a highlight, we spent the quarter focused on building a solid foundation for 2025," Oren Shuster, the company's CEO, said. "Our goal was to build a strong, consistent supply chain, along with a laser focus on how to improve the efficiency and accuracy of how we use our resources. I believe that the foundation we built this quarter will be the basis we will use to deliver in 2025."
Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) will report the second quarter of fiscal year 2025 ended Sept. 30, before financial markets open on Friday, Nov. 8, 2024. IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) a medical cannabis company with operations in Israel and Germany, will report operational and financial results for the third quarter ended Sept. 30 on Nov. 14, 2024, before the market opens. Auxly Cannabis Group Inc. (TSX: XLY) (OTCQB: CBWTF) will report earnings results for its third quarter ended Sept. 30 on Friday, Nov. 8, 2024, before the financial markets open.
The U.S. Hemp Roundtable made headlines in early September as its board of directors welcomed two distinguished leaders from the hemp beverage sector to its officer ranks. New York's chief equity officer at the state Office of Cannabis Management, Damian Fagon, has formally resigned, effective November 27.
Medical cannabis company with operations in Israel and Germany, IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC), intends to undertake a non-brokered private placement offering of up to $1,613,000 through the sale of roughly 625,000 units. What Happened: Each unit will be comprised of one share and one share purchase warrant, with each warrant entitling the holder to acquire one additional share at a price equal to a 50% premium to the offering price before the second anniversary of the closing date. The company plans to close the offering in one or more tranches. It will be led by the company's management team, including Oren Shuster, CEO and chairman of the board of directors and Shmulik Arbel, a director of the company.
Spain's Ministry of Health revealed this week a draft royal decree for public consultation, outlining the suggested regulations for prescribing cannabis-based medications, reported Business of Cannabis. The news comes after years of negotiation and an increase in the legal production of medical cannabis, as earlier reported.
The company, announced its financial results Wednesday for the second quarter ended June 30, 2024, revealing a 12% year-over-year increase in revenue to CA$14.8 million in the second quarter of 2023. The company also reported a 129% year-over-year increase in IMC Germany sales to CA$3.5 million, making up 24% of the entire company revenue.
Medical cannabis company IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC), with operations in Israel and Germany, will report operational and financial results for the second quarter of 2024 ended June 30, 2024, on Wednesday, Aug. 14, 2024. cbdMD, Inc. (NYSE: YCBD) said it will host a conference call at 4:20 pm Eastern Time, on Wednesday, Aug. 14, 2024, to discuss the company's June 30, 2024 third quarter of fiscal 2024 financial results and business progress. Canadian cannabis producer and distributor Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:4WE) its second quarter 2024 financial results will be released after market close on Monday, Aug. 26, 2024. The company will host a conference call to discuss the results and provide an operational update and recap of achievements on Tuesday, Aug. 27, 2024. Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. will report earnings results for its third quarter fiscal 2024 ended June 30, 2024, on Tuesday, Aug. 13, 2024, before market open. The company will host a conference call to discuss its results with details the same day at 8:00 am Eastern Time.
Some European cannabis companies are already planning initial public offerings (IPOs) on the Nasdaq, encouraged by the prospect of a less restrictive regulatory environment. The potential rescheduling of cannabis to Schedule III of the Controlled Substances Act and Germany’s recent decriminalization have ignited optimism within the sector.
